UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 316

Sortiert nach

Rifaximin Treatment in Hepatic Encephalopathy

The New England journal of medicine, 2010-03, Vol.362 (12), p.1071-1081

2010

Volltextzugriff (PDF)

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Clinical gastroenterology and hepatology, 2014-08, Vol.12 (8), p.1390-1397.e2

2014

Volltextzugriff (PDF)

A Fast and Frugal Finance: Bridging Contemporary Behavioral Finance and Ecological Rationality

1, 2019

Volltextzugriff (PDF)

Repeat Treatment With Rifaximin is Safe and Effective in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Gastroenterology (New York, N.Y. 1943), 2016-12, Vol.151 (6), p.1113-1121

2016

Volltextzugriff (PDF)

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

The American journal of medicine, 2000-11, Vol.109 (7), p.523-530

2000

Volltextzugriff (PDF)

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

The New England journal of medicine, 2011-01, Vol.364 (1), p.22-32

2011

Volltextzugriff (PDF)

Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.740-750.e2

2015

Volltextzugriff (PDF)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

Journal of Crohn's and colitis, 2017-07, Vol.11 (7), p.785-791

2017

Volltextzugriff (PDF)

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension

Journal of palliative medicine, 2015-07, Vol.18 (7), p.593

2015

Volltextzugriff (PDF)

The Effect of Multiple-Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers

Pharmacotherapy, 2007-10, Vol.27 (10), p.1361-1369

2007

Volltextzugriff (PDF)

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis

Regional anesthesia and pain medicine, 2016-01, Vol.41 (1), p.93-98

2016

Volltextzugriff (PDF)

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

The American journal of cardiology, 2002-12, Vol.90 (12), p.1314-1319

2002

Volltextzugriff (PDF)

Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial

Journal of clinical gastroenterology, 2016-04, Vol.50 (4), p.318-325

2016

Volltextzugriff (PDF)

Mo1291 Improvements in IBS-Related Quality of Life in a Randomized, Controlled Repeat Treatment Trial (TARGET 3) of Rifaximin for IBS-D

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-663-S-663

2015

Volltextzugriff (PDF)

Mo1275 Safety and Tolerability of Rifaximin in a Repeat Treatment Study in Subjects With IBS-D: Results From TARGET 3

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-657-S-658

2015

Volltextzugriff (PDF)

Mo1268 Characterization of Stool Microbiota in Subjects With IBS-D Receiving Repeat Treatments With Rifaximin in the TARGET 3 Study

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-655-S-655

2015

Volltextzugriff (PDF)

Unconscious thoughts as a spur and halt on good financial decisioning making

International review of financial analysis, 2024-01, Vol.91, p.103012, Article 103012

Forbes, William

2024

Volltextzugriff (PDF)

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis

Digestive diseases and sciences, 2015-11, Vol.60 (11), p.3408-3417

2015

Volltextzugriff (PDF)

313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-69-S-69

2015

Volltextzugriff (PDF)

Mo1267 Rifaximin for IBS-D: Consistent Treatment Effect Across Demographic and Baseline Disease Characteristics

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-654-S-655

2015

Volltextzugriff (PDF)

Mo1269 Enduring Effects Following a Course of Rifaximin Therapy in Patients With IBS-D: Incremental Benefit Upon Repeat Treatment

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-655-S-655

2015

Volltextzugriff (PDF)

Mo1261 Characterizing the Effect of Rifaximin on Individual Symptoms of IBS-D: Findings From the Open-Label Phase of TARGET 3

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-653-S-653

2015

Volltextzugriff (PDF)

Mo1279 Durability of Benefit in IBS-D Patients Responding to a 2-Week Course of Rifaximin: Results From TARGET 3

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-658-S-659

2015

Volltextzugriff (PDF)

Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis

Inflammatory bowel diseases, 2014-08, Vol.20 (8), p.1399-1406

2014

Volltextzugriff (PDF)

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Digestive diseases and sciences, 2016-01, Vol.61 (1), p.221-229

2016

Volltextzugriff (PDF)

1 – 25 von 316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(253)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Rifaximin Treatment in Hepatic Encephalopathy

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

A Fast and Frugal Finance: Bridging Contemporary Behavioral Finance and Ecological Rationality

Repeat Treatment With Rifaximin is Safe and Effective in Patients With Diarrhea-predominant Irritable Bowel Syndrome

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension

The Effect of Multiple-Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial

Mo1291 Improvements in IBS-Related Quality of Life in a Randomized, Controlled Repeat Treatment Trial (TARGET 3) of Rifaximin for IBS-D

Mo1275 Safety and Tolerability of Rifaximin in a Repeat Treatment Study in Subjects With IBS-D: Results From TARGET 3

Mo1268 Characterization of Stool Microbiota in Subjects With IBS-D Receiving Repeat Treatments With Rifaximin in the TARGET 3 Study

Unconscious thoughts as a spur and halt on good financial decisioning making

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis

313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study

Mo1267 Rifaximin for IBS-D: Consistent Treatment Effect Across Demographic and Baseline Disease Characteristics

Mo1269 Enduring Effects Following a Course of Rifaximin Therapy in Patients With IBS-D: Incremental Benefit Upon Repeat Treatment

Mo1261 Characterizing the Effect of Rifaximin on Individual Symptoms of IBS-D: Findings From the Open-Label Phase of TARGET 3

Mo1279 Durability of Benefit in IBS-D Patients Responding to a 2-Week Course of Rifaximin: Results From TARGET 3

Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Suchergebnisse filtern